MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.86
+0.09
+1.33%
Closed 18:16 03/03 EST
OPEN
6.80
PREV CLOSE
6.77
HIGH
7.07
LOW
6.73
VOLUME
804.41K
TURNOVER
--
52 WEEK HIGH
8.33
52 WEEK LOW
4.220
MARKET CAP
619.10M
P/E (TTM)
-6.7407
1D
5D
1M
3M
1Y
5Y
Ardelyx, Inc. (NASDAQ:ARDX): When Will It Breakeven?
We feel now is a pretty good time to analyse Ardelyx, Inc.'s ( NASDAQ:ARDX ) business as it appears the company may be...
Simply Wall St. · 2d ago
BRIEF-Knight Therapeutics Says Has Exclusive Right To Commercialize Ibsrela In Canada Under Terms Of A License Agreement Entered Into With Ardelyx
reuters.com · 2d ago
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
GlobeNewswire · 2d ago
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks.com · 5d ago
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 5d ago
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive offic...
PR Newswire · 02/17 13:00
10 Best Small-Cap Biotech Stocks Under $10 in 2021
In this article we will list the 10 best small-cap biotech stocks under $10 in 2021. Click to skip ahead and see the 5 Best Small-Cap Biotech Stocks Under $10 in 2021. We like healthcare and technology industries because of their above-average long-term gr...
Insider Monkey · 02/08 15:11
Is Ardelyx, Inc. (NASDAQ:ARDX) Popular Amongst Institutions?
The big shareholder groups in Ardelyx, Inc. ( NASDAQ:ARDX ) have power over the company. Large companies usually have...
Simply Wall St. · 01/16 06:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARDX stock price target is 14.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 87.21M
% Owned: 96.63%
Shares Outstanding: 90.25M
TypeInstitutionsShares
Increased
34
2.85M
New
32
1.92M
Decreased
40
2.98M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Gordon Ringold
Independent Director
Richard Rodgers
No Data
About ARDX
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.